1.      Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2002;24(1):9–13.

2.      Barton CD, Waugh LK, Nielsen MJ, Paulus S. Febrile neutropenia in children treated for malignancy. J Infect. 2015;71 Suppl 1:S27–S35.

3.      Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia. 2016;30(1):32–38. Available from: https://www.nature.com/articles/leu2015199

4.      Bolouri H, Farrar JE, Triche TJ Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103–112.

5.      Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014;28(1):70–77.

6.      Clarke RT, van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJ. Clinical presentation of childhood leukaemia: a systematic review and meta-analysis. Arch Dis Child. 2016;101(10):894–901.

7.      Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with acute myeloid leukemia. Pediatr Blood Cancer. 2007;48(6):651–662.

8.      Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384–4393.

9.      Fish JD, Lipton JM, Lanzkowsky P, editors. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th ed. London: Academic Press; 2021. p. 403–447.

10.  Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood. 2011;118(26):6752–6759.

11.  Getz KD, Sung L, Ky B, et al. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children’s Oncology Group. J Clin Oncol. 2019;37(1):12–21.

12.  Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol. 2011;155(3):366–376.

13.  Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136(16):1803–1812. Available from: https://ashpublications.org/blood/article/136/16/1803/461194

14.  Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–2539.

15.  Izraeli S, Vora A, Zwaan CM, Whitlock J. How I treat ALL in Down syndrome: pathobiology and management. Blood. 2014;123(1):35–40.

16.  Johnston DL, Alonzo TA, Gerbing RB, et al. Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;58(4):519–524.

17.  Kaspers GJL, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599–607.

18.  Klusmann JH, Creutzig U, Zimmermann M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111(6):2991–2998.

19.  Kulczycka M, Derlatka K, Tasior J, Sygacz M, Lejman M, Zawitkowska J. Infant acute lymphoblastic leukemia—new therapeutic opportunities. Int J Mol Sci. 2024;25(7):3721.

20.  Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer Group Studies 2861 and 2891. Blood. 1998;91(2):608–615.

21.  Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric acute myeloid leukemia. Blood. 2006;108(12):3654–3661.

22.  Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2016;101(4):407–416. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5004393/

23.  O’Brien MM, Taub JW, Chang MN, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children’s Oncology Group Study POG 9421. J Clin Oncol. 2008;26(3):414–420.

24.  Okamoto Y, Ribeiro RC, Srivastava DK, et al. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2003;25(9):696–703.

25.  Patterson TF, Thompson GR III, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.

26.  Pollard JA, Alonzo TA, Gerbing RB, et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD-positive acute myeloid leukemia: a report from the Children’s Oncology Group protocol AAML1031. J Clin Oncol. 2022;40(18):2023–2033.

27.  Ritchey AK, Friehling ED, Meade JC, Tubergen DG, Bleyer A. The leukemias. In: Kliegman RM, St Geme JW III, editors. Nelson Textbook of Pediatrics. 22nd ed. Philadelphia: Elsevier; 2024. p. 3097–3105.

28.  Rizzari C, Szczepanski T, Ampatzidou M, Gotti G, Stutterheim J. European Standard Clinical Practice: Acute Lymphoblastic Leukemia (ALL). Brussels: European Society for Paediatric Oncology (SIOPE), European Reference Network PaedCan; 2022. Available from: https://siope.eu/media/documents/european-standard-clinical-practice-acute-lymphoblastic-leukemia.pdf

29.  Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.

30.  Yamaguchi M, Kurokawa T, Ishiyama K, et al. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Ann Hematol. 2011;90(10):1209–1217.